ARA-290

• Week 1-2: Trial (4 mg): nerve pain got in the way less, right away
• Week 2-4: Trial (4 mg): less nerve-pain disruption by week 3
• Week 4-8: Break; in trials, benefits held after shots stopped
• Week 8-12: Break; see a doctor if nerve symptoms spread or worsen
• Side effects: 911: face or throat swelling, trouble breathing; kidney signs: stop

More on each stage

Week 1-2

Trial results below come from 4 mg a day, the top of the dose range. In a sarcoidosis trial, the ARA-290 group reported an immediate drop in how much nerve pain got in the way of daily life.

Week 2-4

In the same trial, the drop in how much pain disrupted daily life was clearly better than placebo by week 3. By day 28, nerve-symptom scores had fallen about 28% (vs. 9% on placebo), small nerve fibres in the eye had grown back about 15%, and people walked farther. Your 4 weeks on end here.

Week 4-8

You are on the break. In the trials, benefits held after the shots stopped: in a diabetes trial, the gap in nerve symptoms between ARA-290 and placebo grew wider 4 weeks after the last dose. Notice whether burning, tingling, or numbness stays better.

Week 8-12

Still on the break until the end of week 12. In the sarcoidosis trial, symptom scores were still better than placebo 12 weeks after the last dose. If nerve symptoms are spreading or getting worse, see a doctor: neuropathy has many causes that need proper testing.

Side effects

Trials found mild side effects about as often as on placebo, with no injection-site irritation. One trial patient with weak kidneys got worse. Stop and get help for face or throat swelling or trouble breathing.

Based on what people report in the community sources below. Results vary, and many responses are anecdotal.

• Fewer nerve symptoms in sarcoidosis

  Clinical trial

  In two placebo-controlled trials of people with small-fibre nerve damage from sarcoidosis, nerve-symptom scores fell far more on ARA-290: 11.5 vs. 2.9 points after 4 weeks of 2 mg into a vein 3 times a week (22 people), and 12.2 vs. 3.8 points (about 28% vs. 9%) after 28 days of 4 mg a day under the skin (38 people). The second benefit was still there 12 weeks later.12

• Small nerve fibres grew back

  Clinical trial

  Small nerve fibres in the cornea (the clear front of the eye, a window on nerve health) grew back by a median 14.5% after 28 days of 4 mg a day. In a 64-person trial, 4 mg a day raised corneal nerve fibre area and regrowing nerve fibres in the skin.24

• Walked farther

  Clinical trial

  In the sarcoidosis trial, people on 4 mg a day walked 18.7 m farther in a 6-minute walk test, while the placebo group walked 15.1 m less.2

• Less nerve pain and slightly better blood sugar in type 2 diabetes

  Clinical trial

  In 48 people with type 2 diabetes and painful nerve damage, 4 mg a day for 28 days improved a nerve-pain questionnaire (3.3 vs. 1.1 points at day 28, 4.2 vs. 0.7 at day 56). Long-term blood sugar (HbA1c) dipped slightly, by 0.16% at day 28 vs. 0.01% on placebo.3

• Long-lasting nerve pain relief in rats

  Animal/lab study

  After a nerve injury, rats given ARA-290 had less touch and cold pain for as long as 15 weeks. It did nothing in mice missing part of its receptor (the beta common receptor), showing it works through that receptor.8

• Does not raise red blood cells

  Clinical trial

  ARA-290 is built from a small piece of EPO, the hormone that makes red blood cells, but it does not boost red blood cell production in animals. Trials found no meaningful blood-count changes and no antibodies against it.732

• Nerve-symptom relief

  Community report

  Community users with diagnosed neuropathy report improvement in nerve symptoms, and some report better thinking or nerve function.14

What it has been studied for

• Nerve pain and small-fibre nerve damage from sarcoidosis (an inflammatory disease)124Clinical trial
• Painful nerve damage in type 2 diabetes, and blood sugar control3Clinical trial
• Nerve-injury pain8Animal/lab study
• Heart-muscle damage after a heart attack9Animal/lab study
• Burn wounds that spread deeper10Animal/lab study

ARA-290 is a copy of one small part of EPO, a hormone your body makes, only 11 building blocks (amino acids) long. EPO has two jobs, making red blood cells and repairing tissue, and each job uses a different doorway (receptor) on cells. ARA-290 skips the red-blood-cell doorway. The repair doorway barely shows up on healthy tissue, but injury or inflammation switches it on. ARA-290 locks onto it there, turns down inflammation alarms, and helps the tissue protect and repair itself. It leaves the blood within minutes, but it seems to flip a lasting switch: its effects can last for weeks.

Peak

After a 4 mg shot under the skin, healthy volunteers reached a peak blood level of about 3 ng/mL. The time to that peak has not been published.

Half-life

About 20 minutes after a 4 mg shot under the skin (healthy volunteers). About 2 minutes after injection into a vein in rats and rabbits.

Cleared

Not measured directly. At a 20-minute half-life, the usual rule of about 5 half-lives means it should be gone from the blood within about 2 hours. Its effects last far longer: trial benefits persisted for weeks to months after the last dose.

Half-life is how long it takes the body to remove half of a dose.3762

Once a day. Morning. No study shows a best time of day; the trials did not say when people injected. Every day. Units are for a 10 mg vial mixed with 1 mL water (10 mg per mL).

Research protocols

• Sarcoidosis nerve-symptom pilot trial (22 people)

  2 mg ARA-290 into a vein, 3 times a week for 4 weeks, vs. placebo.1

• Sarcoidosis small-fibre nerve trial (38 people)

  4 mg under the skin once a day for 28 days, injected into the upper leg or lower belly, then 12 weeks of follow-up off the drug.2

• Type 2 diabetes with painful nerve damage (48 people analysed)

  4 mg under the skin once a day for 28 days, self-injected into the front of the thigh with rotating sites, then 28 days off.3

• Sarcoidosis dose-comparison trial (phase 2b, 64 people)

  1, 4, or 8 mg a day for 28 days vs. placebo. 4 mg a day significantly increased corneal nerve fibre area.4

• Biohacking community (Peptide Protocol Wiki, 15 reports; not a study)

  Most follow the trials: 2 to 4 mg under the skin once a day for 28 to 84 days. A lower plan uses 1 to 2 mg once a day for 4 to 8 weeks.14

There is no real community dosing consensus for ARA-290 because almost no one can get it. Most forum talk points back to the published sarcoidosis- and neuropathy-trial schedules rather than self-experimentation.

Dosing guidance built from the cited research and community reports. It is not a prescription.

1. 1
2. 2
3. 3
4. 4
5. 5
6. 6
7. 7
8. 8
9. 9
10. 10
11. 11
12. 12

On: 4 weeks Break: 8 weeks

A full course at the store pace takes 2 vials. A mixed vial keeps for up to 90 days.

Why the break helps

The human trials ran 28 days, the same length as the 4-week course, so the break keeps your use within what has been tested. In those trials, benefits outlasted the shots: symptom scores stayed better 12 weeks after the last dose, and partly at 9 months. The 8-week break lets you see whether your nerves stay calmer without it.

Common

• Mild, short-lived complaints. In the diabetes trial, mild side effects were about as common on placebo as on ARA-290 (54 vs. 61 mild events). The sarcoidosis trials found no safety concerns.

  What to do Keep a short note of what you feel and when. If something bothers you, skip a day; if it keeps happening, stop.

• Redness or soreness where you injected. The 4 mg trial saw no pain or irritation at the injection site, but any injection can cause it.

  What to do Rotate sites and use a fresh syringe every time. It usually fades on its own. If redness spreads or gets hot and painful, treat it as an infection (see below).

Stop and get help

• Kidney function getting worse: much less urine, new swelling in the legs or ankles, or unusual tiredness. In the diabetes trial, one patient with borderline kidney function who took a water pill (furosemide) got worse; doctors judged it possibly related and stopped the drug.

  What to do Stop ARA-290 and see a doctor promptly for a kidney blood test.

• Allergic reaction: hives, swelling of the face, lips, or throat, trouble breathing, or feeling faint.

  What to do Stop and call 911 (or your local emergency number) right away.

• Infection at the injection site: redness that spreads, heat, pus, red streaks, or fever.

  What to do Stop injecting and see a doctor the same day.

Do not use if

• You are pregnant, trying to get pregnant, or breastfeeding: there is no safety data.
• You are under 18: it has only been tested in adults.
• You have kidney disease, unless your doctor agrees and checks your kidney blood tests: one trial patient with weak kidneys got worse.
• You compete in a drug-tested sport: WADA bans innate repair receptor agonists at all times.

Storage

Keep it

Keep the mixed vial in the fridge (2-8 °C / 36-46 °F), away from heat and light, and never in a hot car. Do not use it if it turns cloudy or has specks.

How long

Use within 90 days of mixing. A mixed vial kept in the fridge holds its strength for 60-90 days, then slowly starts to lose potency. Wipe the rubber top with an alcohol swab before every draw.

Drawing your dose

Syringe: a 0.5 mL (50-unit) U-100 insulin syringe.

1. With this mix, every 1 unit line on a U-100 insulin syringe holds 100 mcg. Draw to the 5-unit line for 500 mcg.
2. The last draw from a vial can come up a little short, because a few drops stay in the vial; tilt the vial and pull from the lowest point.
3. Hold the syringe at eye level, flick out air bubbles, and push the plunger back to the exact line.
4. Pinch a fold of skin on the lower belly or front of the thigh, insert the needle at 45 to 90 degrees, push slowly, and wait a few seconds before pulling out.
5. Use a new sterile syringe every time and never share one.

• BPC-157

  The most common community stack, aimed at nerve protection plus tissue healing. BPC-157 sped up regrowth of cut nerves in rats, while ARA-290 eased nerve symptoms in human trials.1411

• Semax

  Community users pair it with Semax for brain and nerve protection.14

Interactions

• Diabetes medicines that can drop blood sugar (insulin, sulfonylureas such as glipizide)

  ARA-290 slightly lowered long-term blood sugar in a diabetes trial. No interaction studies exist.

  What to do Check your blood sugar more often for the first weeks and tell your doctor you use it. Do not change your prescribed medicine on your own.

• Water pills (diuretics such as furosemide) or any kidney condition

  One trial patient with borderline kidney function who took furosemide had worse kidney function on ARA-290, judged possibly related.

  What to do Ask your doctor first and get a kidney blood test before and during use.

• Other peptides in a stack (BPC-157, Semax, TB-500)

  Starting several peptides at once makes it hard to tell which one causes a reaction.

  What to do Start one peptide at a time, a week or more apart, so you can tell which one causes a problem.

Sources

1. 1Heij et al., Mol Med 2012 (ARA 290 in sarcoidosis nerve symptoms, 2 mg IV pilot trial)Clinical trial
2. 2Dahan et al., Mol Med 2013 (ARA 290 4 mg daily in sarcoidosis small-fibre nerve loss)Clinical trial
3. 3Brines et al., Mol Med 2015 (ARA 290 in type 2 diabetes with painful neuropathy)Clinical trial
4. 4Culver et al., Invest Ophthalmol Vis Sci 2017 (cibinetide 1, 4, 8 mg dose-comparison trial)Clinical trial
5. 5van Velzen et al., Expert Opin Investig Drugs 2014 (review of ARA 290 sarcoidosis trials)Review
6. 6Collino et al., Pharmacol Ther 2015 (ARA 290 receptor, short half-life, long-lasting effects review)Review
7. 7Brines et al., PNAS 2008 (the EPO helix B peptide: tissue protection without red-cell effects)Study
8. 8Swartjes et al., Anesthesiology 2011 (ARA290 and nerve-injury pain in rats and mice)Study
9. 9Ahmet et al., Mol Med 2011 (helix B peptide protects rat heart after heart attack)Study
10. 10Bohr et al., PNAS 2013 (ARA290 in mouse burn wounds)Study
11. 11Gjurasin et al., Regul Pept 2010 (BPC 157 and cut nerve healing in rats)Study
12. 12European Medicines Agency: orphan designation EU/3/13/1191, cibinetide for sarcoidosisReference
13. 13Finnish Center for Integrity in Sports: 2026 WADA doping classes (S2.1.5 innate repair receptor agonists)Reference
14. 14Peptide Protocol Wiki: ARA-290 community protocols (15 reports)Community

Where people discuss it

• r/Peptides (subreddit)
• Peptide Protocol Wiki — ARA-290 community (15 reports)

Some peptides, like semaglutide (Ozempic and Wegovy), are FDA-approved medicines. Most of the peptides people research are not. That label sounds like the FDA tested something and turned it down. Usually it means something else: nobody has paid for the studies the FDA needs to see. Here is why.

The FDA doesn’t test drugs. Companies do.

The FDA does not run its own drug tests. A company that wants to sell a new medicine has to test it first, and pay for it. It studies the drug in animals, then in people: first 20 to 100 volunteers, then a few hundred, then up to 3,000. Then it sends all the results to the FDA. FDA scientists review them and decide whether the benefits outweigh the risks.

So approval always starts with a company asking for it. If no company applies, the FDA has nothing to review, however promising the research looks.

Those studies cost about a billion dollars

A study in the medical journal JAMA estimated that bringing one new drug to market costs a typical company about $1.1 billion. That figure includes the money spent on drug ideas that failed along the way, because many drugs that start human testing never make it.

A patent is how a company earns that money back

A patent is a right the government gives an inventor. For up to 20 years from the day the inventor applies, nobody else may make or sell the invention without permission.

For a drug company, that right is what makes the billion-dollar bet worth it. While the patent lasts, the company is the only seller, so it can charge enough to pay back the studies and the failures. When the patent runs out, other companies can sell cheap copies, called generics, and the price drops.

The FDA adds a shorter shield of its own. For 5 years after a brand-new drug is approved, no copycat version can apply for approval. That helps, but it is much shorter than a patent can last.

Why most peptides can’t be patented

To get a patent, an invention has to be new, and it has to be something people made, not something found in nature. Most popular peptides fail one test or both.

They come from nature. Many are copies or small pieces of molecules your body already makes. KPV is a 3-building-block piece of the hormone that tans your skin. BPC-157 is copied from a protein in stomach juice. In 2013 the US Supreme Court ruled that something that exists in nature, like a human gene, cannot be patented just because someone found it and pulled it out.

They aren’t new anymore. Many were first described in research papers decades ago. Scientists were already testing KPV in the 1980s. Once something has been published, it no longer counts as new, so nobody can patent it now, and any patents from back then have long since run out.

Without a patent, a company that paid for the studies would soon face rivals selling the same peptide without having paid for any research. Few companies will spend a billion dollars on a product anyone can copy. So nobody goes first, and the large human studies never happen.

The workaround: change the molecule

Drug companies do make peptide medicines, but they change the peptide first. A changed molecule is a new invention, so it can be patented. Semaglutide is a lab-made version of GLP-1, a gut hormone your body releases after meals, changed so one shot lasts a week. Tesamorelin (Egrifta) is the body’s own growth-hormone signal with a small fatty chain added. Both went through the full studies, and both are FDA-approved.

The natural versions, and the many peptides nobody has changed and patented, stay where they are: studied in labs and animals, used by the biohacking community, and never put through large human trials.

What this means for you

When a peptide is “not FDA-approved,” it usually means no company has paid for the large human studies. It does not mean the FDA tested it and found it harmful.

It also does not mean it is proven safe or proven to work. Without those studies, nobody knows the best dose for sure, or what rare or long-term side effects it may have. And the FDA does not check research peptides for purity or strength the way it checks approved medicines. That is why this page labels every finding by the kind of study behind it, and lists who should not use it.

Sources for this section

1. 1FDA: How drugs are developed and approved (the FDA does not test drugs; companies submit the evidence)
2. 2FDA: The drug development process, step 3: clinical research (study sizes for each phase)
3. 3Wouters, McKee & Luyten, JAMA 2020, corrected 2022: median cost to bring a new drug to market, $1.14 billion
4. 4US patent law, 35 U.S.C. § 154: a patent lasts 20 years from the filing date
5. 5FDA: Frequently asked questions on patents and exclusivity (5-year new chemical entity exclusivity)
6. 6US Supreme Court, Association for Molecular Pathology v. Myriad Genetics (2013): naturally occurring genes cannot be patented